Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2001
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
AIDS Vaccines in the New Millennium (J8)
Organizer(s) R. Paul Johnson, Mark B. Feinberg and Emilio A. Emini
March 28—April 3, 2001
Keystone Resort • Keystone, CO USA
Abstract Deadline: Nov 28, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 29, 2001
Sponsored by Wyeth-Lederle Vaccines
Joint Meeting:
HIV Pathogenesis (J7)
Summary of Meeting:
The last few years have witnessed remarkable progress in scientific studies relevant to the development of an AIDS vaccine. Emerging data from both human and animal studies are providing novel insights into the immunological mechanisms that contain HIV infection. A variety of new vaccine approaches show promise in inducing a broad range of immune responses, and are now being tested in animal models and human clinical trials. Several recent technical advances have provided critical information on the structure of the envelope glycoprotein and new tools for the quantitative analysis of immune responses. Yet, many fundamental and practical challenges remain, and it is unclear whether any of the existing approaches will result in a safe and effective AIDS vaccine. This Keystone Symposium is intended to foster communication of the most current results, from basic and applied HIV vaccine research efforts, to integrate this information in the context of recent advances on AIDS pathogenesis, to identify and address obstacles to vaccine development, and to stimulate accelerated research on HIV vaccines.
View Scholarships/Awards
The last few years have witnessed remarkable progress in scientific studies relevant to the development of an AIDS vaccine. Emerging data from both human and animal studies are providing novel insights into the immunological mechanisms that contain HIV infection. A variety of new vaccine approaches show promise in inducing a broad range of immune responses, and are now being tested in animal models and human clinical trials. Several recent technical advances have provided critical information on the structure of the envelope glycoprotein and new tools for the quantitative analysis of immune responses. Yet, many fundamental and practical challenges remain, and it is unclear whether any of the existing approaches will result in a safe and effective AIDS vaccine. This Keystone Symposium is intended to foster communication of the most current results, from basic and applied HIV vaccine research efforts, to integrate this information in the context of recent advances on AIDS pathogenesis, to identify and address obstacles to vaccine development, and to stimulate accelerated research on HIV vaccines.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
WEDNESDAY, MARCH 28
THURSDAY, MARCH 29
FRIDAY, MARCH 30
SATURDAY, MARCH 31
SUNDAY, APRIL 1
MONDAY, APRIL 2
TUESDAY, APRIL 3
Conference Program Print | View meeting in 12 hr (am/pm) time
WEDNESDAY, MARCH 28
19:30—21:30
Keynote Address (Joint)
Gary J. Nabel,
Sanofi, USA
AIDS Vaccines: Challenges and Opportunities
AIDS Vaccines: Challenges and Opportunities
Ashley T. Haase,
University of Minnesota, USA
Life in the Fast Lane in a Slow Infection: Implications for Vaccine Development of Events in Early Infection
Life in the Fast Lane in a Slow Infection: Implications for Vaccine Development of Events in Early Infection
08:00—11:00
Cellular Immune Responses and Protective Immunity (Joint)
Dan H. Barouch,
Beth Israel Deaconess Medical Center, USA
Vaccine-Elicited Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys
Vaccine-Elicited Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys
R. Paul Johnson,
Harvard Medical School, USA
Protective Immunity Induced by Attenuated Simian Immunodeficiency Virus
Protective Immunity Induced by Attenuated Simian Immunodeficiency Virus
14:00—16:00
VACCINES WORKSHOP 1: Biological Considerations in the Evaluation of Candidate AIDS Vaccines
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
The Implications of Global Variation of HIV for Vaccine Design
The Implications of Global Variation of HIV for Vaccine Design
Philip J. Goulder,
University of Oxford, UK
Analysis of HIV-1 Specific CTL Responses in South Africa Adults and Children
Analysis of HIV-1 Specific CTL Responses in South Africa Adults and Children
Mary Carrington,
NCI, National Institutes of Health, USA
HLA Diversity and AIDS Vaccine Trials
HLA Diversity and AIDS Vaccine Trials
14:00—16:00
WORKSHOP 1: Soluble Modulators of HIV Infection
*
Jay A. Levy,
University of California, San Francisco, USA
CD8+ Cell Noncytotoxic Anti-HIV Response Can Prevent Virus Infection and Pathogenesis
CD8+ Cell Noncytotoxic Anti-HIV Response Can Prevent Virus Infection and Pathogenesis
Paolo Lusso,
NIAID, National Institutes of Health, USA
Chemokines and Derivatives as Potential Anti-HIV Agents
Chemokines and Derivatives as Potential Anti-HIV Agents
Reinhard Kurth,
Ernst Schering Foundation, Germany
HIV-Pathogenesis: What Protects the SIV-Infected Natural Host Primate from Development of AIDS?
HIV-Pathogenesis: What Protects the SIV-Infected Natural Host Primate from Development of AIDS?
J. Norman Flynn,
University of Glasgow, UK
Involvement of Cytolytic and Non-Cytolytic T Cells in the Control of Feline Immunodeficiency Virus
Involvement of Cytolytic and Non-Cytolytic T Cells in the Control of Feline Immunodeficiency Virus
Tae-Wook Chun,
NIAID, National Institutes of Health, USA
Suppression of HIV Replication in the Resting CD4+ T Cell Reservoir by Autologous CD8+ T Cells: Implications for the Development of the Therapeutic Strategies
Suppression of HIV Replication in the Resting CD4+ T Cell Reservoir by Autologous CD8+ T Cells: Implications for the Development of the Therapeutic Strategies
Karen F.T. Copeland,
Ottawa Hospital Research Institute, Canada
Role of CD8+ T Cell Infection on Cellular Function
Role of CD8+ T Cell Infection on Cellular Function
Mary E. Klotman,
Mount Sinai School of Medicine, USA
Purification and Characterization of Soluble HIV Suppressive Factors from CD8+ Cells
Purification and Characterization of Soluble HIV Suppressive Factors from CD8+ Cells
David J. Volsky,
Columbia University, St. Luke's Roosevelt Hospital Center, USA
Induction of Secretable Anti-HIV Factor in CD4-Positive T Cells
Induction of Secretable Anti-HIV Factor in CD4-Positive T Cells
16:00—18:00
POSTER SESSION 1: Cellular Immune Responses and Protective Immunity/Envelope Glycoprotein: Structure, Function and Immune Responses
20:00—22:00
Envelope Glycoprotein: Structure, Function and Immune Responses (Joint)
William C. Olson,
Regeneron Pharmaceuticals, Inc., USA
Studies on Disulfide-Stabilized HIV Envelope Glycoproteins
Studies on Disulfide-Stabilized HIV Envelope Glycoproteins
*
James A. Hoxie,
University of Pennsylvania, USA
Lessons Learned from CD4 Independent Isolates of HIV and SIV
Lessons Learned from CD4 Independent Isolates of HIV and SIV
Peter S. Kim,
Stanford University, USA
Inhibiting HIV Entry
Inhibiting HIV Entry
Erica Ollmann Saphire,
La Jolla Institute for Immunology, USA
Short Talk: The Crystal Structure of IgG1 b12: Implications for Vaccine Design and Antibody Neutralization
Short Talk: The Crystal Structure of IgG1 b12: Implications for Vaccine Design and Antibody Neutralization
08:00—11:00
Antiviral Immunity and Antigen Processing (Joint)
*
Rafi Ahmed,
Emory University School of Medicine, USA
Vaccines and Immune Memory
Vaccines and Immune Memory
Kenneth L. Rock,
University of Massachusetts Medical School, USA
Immune Surveillance of Viral Infections
Immune Surveillance of Viral Infections
Francis V. Chisari,
The Scripps Research Institute, USA
Noncytopathic Control of Viral Infections by the Immune Response
Noncytopathic Control of Viral Infections by the Immune Response
Giuseppe Pantaleo,
Centre Hospitalier Universitaire Vaudois, Switzerland
Skewed Maturation of Memory HIV-Specific CD8 T Lymphocytes
Skewed Maturation of Memory HIV-Specific CD8 T Lymphocytes
16:00—18:00
POSTER SESSION 2: Antiviral Immunity and Antigen Processing/Novel Vaccine Approaches
20:00—22:00
Novel Vaccine Approaches
*
Mark B. Feinberg,
IAVI International AIDS Vaccine Initiative, USA
Robert E. Johnston,
Global Vaccines, Inc., USA
Alphavirus Vaccine Vectors
Alphavirus Vaccine Vectors
Philip R. Johnson,
Children's Hospital of Philadelphia, USA
Novel SIV/HIV Vaccines Based on Recombinant Adeno-Associated Virus Vectors
Novel SIV/HIV Vaccines Based on Recombinant Adeno-Associated Virus Vectors
Mark J. Newman,
Geovax Inc, USA
The Multi-Epitope Approach to Development of HIV Vaccines
The Multi-Epitope Approach to Development of HIV Vaccines
20:00—22:00
Viral Life Cycle
Mario Stevenson,
University of Miami, Leonard M. Miller School of Medicine, USA
Role of Primate Lentiviral Nef Proteins in Altering Permissiveness of the Host to Viral Replication
Role of Primate Lentiviral Nef Proteins in Altering Permissiveness of the Host to Viral Replication
*
Warner Craig Greene,
Gladstone Institute of Virology and Immunology, USA
Host-Virus Interactions and HIV Pathogenesis
Host-Virus Interactions and HIV Pathogenesis
08:00—11:00
HIV Persistence - Challenges for Elimination (Joint)
*
Robert F. Siliciano,
Johns Hopkins University School of Medicine, USA
Persistent Reservoirs of HIV
Persistent Reservoirs of HIV
Mark Dybul,
National Institutes of Health, USA
David D. Ho,
Aaron Diamond AIDS Research Center (ADARC), Columbia University Medical Center, USA
The Persistence of the Latent Reservoir on Antiretroviral Therapy is Exacerbated by Incomplete Suppression of HIV-1 Replication
The Persistence of the Latent Reservoir on Antiretroviral Therapy is Exacerbated by Incomplete Suppression of HIV-1 Replication
James I. Mullins,
University of Washington, USA
Compartments and Reservoirs of HIV Infection in vivo
Compartments and Reservoirs of HIV Infection in vivo
16:00—18:00
POSTER SESSION 3: HIV Persistence/Novel Vaccine Approaches -Animal Studies
20:00—22:30
Novel Vaccine Approaches - Animal Studies
*
Neal NMI Nathanson,
University of Pennsylvania, USA
Harriet L. Robinson,
GeoVax Inc., USA
Multiprotein DNA/MVA Vaccine, Control of a Mucosal Challenge and Prevention of AIDS by a Memory T Cell Response
Multiprotein DNA/MVA Vaccine, Control of a Mucosal Challenge and Prevention of AIDS by a Memory T Cell Response
John W. Shiver,
Sanofi Pasteur, USA
Comparative Studies of Several HIV Vaccine Approaches
Comparative Studies of Several HIV Vaccine Approaches
20:00—22:00
HIV Receptors, Tropism
*
Julie M. Overbaugh,
Fred Hutchinson Cancer Research Center, USA
Evolution and Selection of T-Cell-Tropic Retroviruses that use Novel Receptors
Evolution and Selection of T-Cell-Tropic Retroviruses that use Novel Receptors
Ronald P. van Rij,
Radboud University Medical Center, Netherlands
HIV-1 Coreceptor Usage and Its Implications for T Cell Tropism in vivo
HIV-1 Coreceptor Usage and Its Implications for T Cell Tropism in vivo
Edward A. Berger,
NIAID, National Institutes of Health, USA
Receptor-Based Intervention Strategies
Receptor-Based Intervention Strategies
Leonid Margolis,
NICHD, National Institutes of Health, USA
Short Talk: Why Different Coreceptor Usage Leads to Different Pathogenesis in Human Lymphoid Tissue
Short Talk: Why Different Coreceptor Usage Leads to Different Pathogenesis in Human Lymphoid Tissue
08:00—11:00
New Investigators/Late Breakers
*
R. Paul Johnson,
Harvard Medical School, USA
Meg Trahey,
University of Montana, USA
Env-CD4-CCR5 Protein Complexes Elicit Antibodies that Neutralize Primary Isolates of HIV-1
Env-CD4-CCR5 Protein Complexes Elicit Antibodies that Neutralize Primary Isolates of HIV-1
David C. Montefiori,
Duke University Medical Center, USA
Neutralizing Antibodies Associated with Viremia Control Following Treatment-Interruption in HIV-1-Infected Individuals
Neutralizing Antibodies Associated with Viremia Control Following Treatment-Interruption in HIV-1-Infected Individuals
Surojit Sarkar,
University of Washington School of Medicine, USA
Fine Specificity Analysis of Broadly Reactive and Type Specific CD4+ T Helper Responses in Macaques Vaccinated with Attenuated Simian Immunodeficiency Virus
Fine Specificity Analysis of Broadly Reactive and Type Specific CD4+ T Helper Responses in Macaques Vaccinated with Attenuated Simian Immunodeficiency Virus
Luzheng Liu,
Brigham and Women's Hospital, USA
A Novel Flow Cytometric Cytotoxicity Assay to Evaluate CTL Responses Against HIV Antigens
A Novel Flow Cytometric Cytotoxicity Assay to Evaluate CTL Responses Against HIV Antigens
Wendy Lisa Trigona,
Merck Research Laboratories, USA
Use of Peptide Mixes for Detecting T Cell Responses to HIV by Cytokine Flow Cytometry
Use of Peptide Mixes for Detecting T Cell Responses to HIV by Cytokine Flow Cytometry
Claudio Vita,
Commissariat Energie Atomique, France
Engineering CD4 Mimics, Inhibiting HIV-1 Entry and Exposing Envelope Neutralizing Epitopes
Engineering CD4 Mimics, Inhibiting HIV-1 Entry and Exposing Envelope Neutralizing Epitopes
Larry A. Harshyne,
Thomas Jefferson University, USA
Live-Cell Antigen Transfer Between Dendritic Cells: Implications for Expanding and Regulating Immune Responses
Live-Cell Antigen Transfer Between Dendritic Cells: Implications for Expanding and Regulating Immune Responses
Shane Crotty,
La Jolla Institute for Immunology, USA
Protection of Macaques from a Virulent SIV(mac251) Vaginal Challenge Using Sabin Strain Live Poliovirus Vaccine Vectors (SabRV) Expressing a Defined Library of SIV Antigens
Protection of Macaques from a Virulent SIV(mac251) Vaginal Challenge Using Sabin Strain Live Poliovirus Vaccine Vectors (SabRV) Expressing a Defined Library of SIV Antigens
David B. Weiner,
Wistar Institute, USA
Plasmid Vaccines Encoding Multiple HIV-1 Antigens Which Includes the Vpr Accessory Gene Markedly Reduce Vaccine Effectiveness and Antigen-Specific Effector T Cell Function in vivo Resulting in CD4 Cell Loss and Increased Viral Loads in Rhesus Macaqu
Plasmid Vaccines Encoding Multiple HIV-1 Antigens Which Includes the Vpr Accessory Gene Markedly Reduce Vaccine Effectiveness and Antigen-Specific Effector T Cell Function in vivo Resulting in CD4 Cell Loss and Increased Viral Loads in Rhesus Macaqu
Jay A. Berzofsky,
NCI, National Institutes of Health, USA
Role of Mucosal Immunization and CTL in Resistance to Mucosal Viral Transmission in Mice and Rhesus Macaques
Role of Mucosal Immunization and CTL in Resistance to Mucosal Viral Transmission in Mice and Rhesus Macaques
Jeffrey D. Lifson,
Leidos Biomedical Research, Inc., USA
Transient Post-Inoculation Antiretroviral Drug Treatment Facilitates Development of SIV-Specific Cellular Immune Responses and Control of Viral Replication in SIV-Infected Rhesus Macaques
Transient Post-Inoculation Antiretroviral Drug Treatment Facilitates Development of SIV-Specific Cellular Immune Responses and Control of Viral Replication in SIV-Infected Rhesus Macaques
08:00—11:00
CD4 Depletion/Renewal/Viral Load
*
Crystal L. Mackall,
Stanford University, USA
Restoring Immune Competence Following T Cell Depletion: It Takes a Village
Restoring Immune Competence Following T Cell Depletion: It Takes a Village
Daniel C. Douek,
NIAID, National Institutes of Health, USA
Thymus Function in HIV Disease
Thymus Function in HIV Disease
Frank Miedema,
Central Laboratories Blood Transfusion, Netherlands
HIV-1 Pathogenesis: Immune Hyperactivation and Failing Thymic Homeostasis
HIV-1 Pathogenesis: Immune Hyperactivation and Failing Thymic Homeostasis
Laura A. Napolitano,
Gladstone Institute of Virology and Immunology, USA
Maintenance of T Cell Homeostasis During the Course of HIV Disease Progression
Maintenance of T Cell Homeostasis During the Course of HIV Disease Progression
14:00—16:00
VACCINE WORKSHOP 2: Practical Considerations in the Evaluation of Candidate AIDS Vaccines
*
Peggy Johnston,
NIAID, National Institutes of Health, USA
Introduction
Introduction
Wayne C. Koff,
Human Vaccines Project, USA
Accelerating AIDS Vaccine Development
Accelerating AIDS Vaccine Development
Rose A. McCullough,
AIDS Vaccine Advocacy Coalition, USA
Community and Advocates Perspectives on AIDS Vaccine Trials
Community and Advocates Perspectives on AIDS Vaccine Trials
Salim S. Abdool Karim,
University of KwaZulu-Natal, South Africa
Perspectives from the Developing World on AIDS Vaccine Trials
Perspectives from the Developing World on AIDS Vaccine Trials
Kathleen M. MacQueen,
Centers for Disease Control, USA
Evolving Ethical Issues and HIV Vaccine Trials
Evolving Ethical Issues and HIV Vaccine Trials
14:00—16:00
WORKSHOP 2: Late Breakers
Jason John Coull,
University of Texas Southwestern Medical Center, USA
Localization of Histone Deacetylase 1 at the Promoter of Inactive Integrated Human Immunodeficiency Virus Type 1
Localization of Histone Deacetylase 1 at the Promoter of Inactive Integrated Human Immunodeficiency Virus Type 1
Silvija I. Staprans,
Bill & Melinda Gates Foundation, USA
AIDS Pathogenesis Elucidated by Divergent Host Responses During SIV Infection of Natural and Non-Natural Hosts
AIDS Pathogenesis Elucidated by Divergent Host Responses During SIV Infection of Natural and Non-Natural Hosts
Victor Appay,
INSERM U1135 - CIMI, France
Difference in CD8+ T Cell Maturation According to Viral Specificity
Difference in CD8+ T Cell Maturation According to Viral Specificity
Jaisri R. Lingappa,
University of Washington, USA
Identification of a Nucleotide-Binding Host Factor Essential for Immature HIV Capsid Assembly
Identification of a Nucleotide-Binding Host Factor Essential for Immature HIV Capsid Assembly
Roger J. Pomerantz,
Seres Therapeutics, Inc., USA
Stratifying Residual HIV-1 Disease and Reservoirs: Virological and Immunological Delineation of Subgroups of HIV-1 Infected Individuals on Suppressive HAART
Stratifying Residual HIV-1 Disease and Reservoirs: Virological and Immunological Delineation of Subgroups of HIV-1 Infected Individuals on Suppressive HAART
Gadi Borkow,
R Ben-Ari Institute of Clinical Immunology, Israel
Melissa J. Churchill,
RMIT University, Australia
Evolution of Promoter Activities of Attenuated Strains of HIV-1
Evolution of Promoter Activities of Attenuated Strains of HIV-1
Homira Behbahani,
Karolinska Institutet, Sweden
Nef-Mediated Inhibition of Perforin Expression
Nef-Mediated Inhibition of Perforin Expression
David McDonald,
National Institute of Allergy and Infectious Disease, USA
Imaging of Cytoplasmic HIV Reverse Transcription Complexes by Correlative Electron Microscopy
Imaging of Cytoplasmic HIV Reverse Transcription Complexes by Correlative Electron Microscopy
16:00—18:00
POSTER SESSION 4: Late Breaking Developments/Mucosal Transmission and Immunity/Clinical HIV Vaccine Trials/Immune Reconstitution
20:00—22:00
Mucosal Transmission and Immunity
Marian R. Neutra,
Children's Hospital Boston, USA
Transport of Antigens and Viruses to the Mucosal Immune System and Induction of Secretory Antibodies on Mucosal Surfaces
Transport of Antigens and Viruses to the Mucosal Immune System and Induction of Secretory Antibodies on Mucosal Surfaces
Christopher J. Miller,
University of California, Davis, USA
Earliest Events in SIV Vaginal Transmission
Earliest Events in SIV Vaginal Transmission
20:00—22:00
Viral Assembly and Release
James E.K. Hildreth,
UC Davis College of Biological Sciences, USA
Adhesion Molecules, Lipid Rafts, and HIV Pathogenesis
Adhesion Molecules, Lipid Rafts, and HIV Pathogenesis
*
Eric O. Freed,
NCI, National Institutes of Health, USA
Viral and Host Determinants of HIV-1 Assembly and Release
Viral and Host Determinants of HIV-1 Assembly and Release
08:00—11:00
Clinical HIV Vaccine Trials
*
Emilio A. Emini,
Bill and Melinda Gates Foundation, USA
Pre-Clinical Evaluation of Merck's HIV Vaccine Candidates Currently in Clinical Trials
Pre-Clinical Evaluation of Merck's HIV Vaccine Candidates Currently in Clinical Trials
Phillip W. Berman,
University of California, Santa Cruz, USA
Development and Clinical Testing of Multivalent gp120 Vaccines
Development and Clinical Testing of Multivalent gp120 Vaccines
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Cellular Immune Responses Induced by Candidate HIV-1 Vaccines
Cellular Immune Responses Induced by Candidate HIV-1 Vaccines
08:00—11:00
Anti-HIV Treatment - Directions and Problems
*
Brenda Lein,
Project Inform, USA
AIDS Therapies: Problems, Potential and Possibilities
AIDS Therapies: Problems, Potential and Possibilities
Alfredo Garzino-Demo†,
University of Maryland School of Medicine, USA
New Biologic Approaches to Control HIV-1
New Biologic Approaches to Control HIV-1
Morris Schambelan,
University of California, San Francisco, USA
Metabolic Consequences of HIV Treatment
Metabolic Consequences of HIV Treatment
16:00—18:00
Immune Reconstitution - Problems and Prospects (Joint)
*
Brigitte Autran,
Hôpital Pitié-Salpétrière, UPMC, France
Immune Reconstitution and Antiviral Therapy
Immune Reconstitution and Antiviral Therapy
Douglas F. Nixon,
Weill Cornell Medicine, USA
Immune Control of HIV Following Antiviral Therapy
Immune Control of HIV Following Antiviral Therapy
Nina Bhardwaj,
Icahn School of Medicine at Mount Sinai, USA
Modulation of Immunity by Dendritic Cells
Modulation of Immunity by Dendritic Cells
*Session Chair †Invited, not yet responded.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
